<DOC>
	<DOCNO>NCT00317486</DOCNO>
	<brief_summary>This study evaluate effect bosentan oxygen saturation , hemodynamics exercise capacity patient pulmonary arterial hypertension relate Eisenmenger physiology . Patients receive bosentan placebo 16 week .</brief_summary>
	<brief_title>Effects Tracleer ( Bosentan ) Pulmonary Arterial Hypertension Related Eisenmenger Physiology</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Eisenmenger Complex</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>1 . Male female patient least 12 year body weight least 40 kg ( inclusive ) functional class III ( 1998 WHO classification ) . 2 . Patients pulmonary arterial hypertension relate Eisenmenger physiology echocardiographically establish atrial septal defect least 2 cm effective diameter and/or ventricular septal defect least 1 cm effective diameter ; PAH confirm via cardiac catheterization : mean pulmonary arterial pressure &gt; 25 mm Hg , pulmonary capillary wedge pressure &lt; 15 mm Hg pulmonary vascular resistance &gt; 3 mm Hg/l/min . 3 . Patients document oxygen saturation 90 % , &gt; 70 % ( rest , room air ) . 4 . Patients able perform 6minute walk test least 150 , 450 m. 5 . Patients stable least 3 month prior screen . 6 . Bosentan naïve patient . 7 . Female patient surgically sterile , postmenopausal document infertility . 8 . Female patient childbearing potential use one follow method contraception : Barriertype device ( e.g. , condom , diaphragm ) use ONLY combination spermicide . A doublebarrier method recommend ; intrauterine device ( IUDs ) ; oral implanted contraceptive , use combination barrier method . 9 . Patients provide write informed consent . 1 . Pregnant patient , nurse mother . 2 . Patients leave ventricular dysfunction ( ejection fraction &lt; 40 % ) . 3 . Patients restrictive lung disease ( TLC &lt; 70 % predict ) ; obstructive lung disease ( FEV1 &lt; 70 % predict , FEV1/FVC &lt; 60 % ) 4 . Patients systolic blood pressure &lt; 85 mm Hg . 5 . Patients condition may affect ability perform 6minute walk test . 6 . Patients unable provide inform consent comply patient protocol . 7 . Patients know coronary arterial disease . 8 . Patients serum creatinine &gt; 125 µM/l . 9 . Patients iron deficiency ( serum ferritin &lt; 10 ng/ml ) unless correct iron supplement . 10 . Patients hemoglobin hematocrit 30 % normal range ( patient secondary polycythemia permit ) . 11 . Patients AST and/or ALT value great 3 time upper limit normal . 12 . Patients start stop treatment PAH within one month screening , exclude anticoagulation . 13 . Patients receive glyburide ( glibenclamide ) , cyclosporine A tacrolimus inclusion expect receive drug study . 14 . Patients receive vasodilator include , limited epoprostenol prostacyclin analogue , expect receive drug study . 15 . Patients active organ transplant list . 16 . Patients take phosphodiesterase inhibitor endothelin receptor antagonist ( bosentan ) investigational drugs/devices . 17 . Patients plan surgical intervention study period . 18 . Cardiac catheterizationspecific exclusion criterion : 1 . Patients safely catheterization perform indicated . 2 . Patients shunt atrial ventricular level . 3 . Patients nonequal pulmonary venous desaturation theoretically correct administration 100 % nonrebreathersupplied oxygen . 4 . Patients nonpulsatile pulmonary blood flow , multiple source pulmonary blood flow . 5 . Patients discontinuous pulmonary artery , peripheral pulmonary arterial venous stenosis &gt; 25 % size native PA create unequal bilateral PA mean pressure , PA band gradient &gt; 20 mm Hg , tetralogy fallot/pulmonary atresia , VSD/pulmonary atresia , DORV/pulmonary atresia , truncus arteriosus , scimitar syndrome . 6 . Patients SVC sample perform , SVC sampling may contaminate 7 . Patients ductus arteriosus . 8 . Patients mitral pulmonary venous stenosis , intracavitary LV outflow obstruction , sub , valvar supravalvar aortic stenosis aortic coarctation . 9 . Patients &lt; 10 indexed Wood unit , great moderate mitral regurgitation , mean pulmonary venous pressure &gt; 16 mm Hg , pulmonary venous `` v '' wave &gt; 20 mm Hg , systemic ventricular enddiastolic pressure &gt; 16 mm Hg ; patient recognize extracardiac systemic venous collateral pulmonary venous circulation , patient recognize hepatic wedge pressureinferior vena cava pressure gradient &gt; 12 mm Hg . 10 . Patients ( catheterization ) uncorrectable hypercarbia pCO2 &gt; 55 mm Hg ; patient uncorrectable acidemia pH &lt; 7.34 ; patient active pain distress ; unconscious mechanically ventilated patient ; patient unstable systemic pulmonary blood flow ; systemic arterial pulmonary artery pressure hematocrit ( change &gt; 25 % catheterization ) ; unstable cardiac rhythm dissimilar baseline cardiac rhythm physical examination assessment entire duration catheterization except nonsustained arrhythmia ; patient document recognize air embolism , hemorrhage , cardiac , cerebral peripheral organ ischemia occur immediately precede catheterization .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>pulmonary arterial hypertension</keyword>
	<keyword>Eisenmenger physiology</keyword>
	<keyword>bosentan</keyword>
</DOC>